Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 22 hours ago
🌐 বাংলায় দেখুন

Indications

Cancer

Alectinib is used on its own (as monotherapy) as the first treatment for adults whose advanced non-small cell lung cancer (NSCLC) is anaplastic lymphoma kinase (ALK)-positive. It is also used on its own for adults with ALK-positive advanced NSCLC who have already been treated with crizotinib.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Alectinib is a highly selective and potent ALK and RET tyrosine kinase inhibitor. In nonclinical studies, blocking ALK tyrosine kinase activity shut down the downstream signaling pathways, including STAT 3 and PI3K/AKT, and this caused tumor cell death (apoptosis). Alectinib was active in vitro and in vivo against mutant forms of the ALK enzyme, including mutations that cause resistance to crizotinib. The major metabolite of alectinib (M4) showed similar potency and activity in vitro.

Nonclinical data show that alectinib is not a substrate of p-glycoprotein (P-gp) or breast cancer resistance protein (BCRP). Both are efflux transporters in the blood brain barrier, so alectinib can distribute into the central nervous system and stay there. In nonclinical mouse xenograft models, alectinib caused tumor regression, including antitumor activity in the brain, and it prolonged survival in intracranial tumor animal models.

Pregnancy & Breastfeeding

Pregnancy: There's little or no data on the use of Alectinib in pregnant women. Going by how the medicine works, Alectinib may harm the foetus when a pregnant woman takes it. Animal studies have shown reproductive toxicity. Female patients who become pregnant while taking Alectinib, or during the 3 months after the last dose, must contact their doctor and should be told about the possible harm to the foetus.

Breast-feeding: It isn't known whether Alectinib and its metabolites pass into human milk, so a risk to the newborn or infant can't be ruled out. Mothers should be advised not to breast-feed while they are receiving Alectinib.

Fertility: No fertility studies have been done in animals to look at the effect of Alectinib. General toxicology studies did not show any adverse effects on the male or female reproductive organs.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: The recommended dose of Alectinib is 600 mg, which is four 150 mg capsules, taken twice daily with food. That makes a total daily dose of 1200 mg. People with severe hepatic impairment (Child-Pugh C) should start at 450 mg twice daily with food, a total daily dose of 900 mg. Duration of treatment Alectinib should be continued until the disease progresses or the side effects become unacceptable. Delayed or missed doses If a planned dose of Alectinib is missed, the patient can make up that dose, unless the next dose is due within 6 hours. Two doses should not be taken at the same time to make up for a missed one. If vomiting happens after a dose of Alectinib, the patient should take the next dose at the usual scheduled time. Dose adjustments Managing adverse events may mean reducing the dose, interrupting treatment for a time, or stopping it altogether. The dose of Alectinib should be lowered in steps of 150 mg twice daily, depending on how well the patient tolerates it. If a patient can't tolerate the 300 mg twice daily dose, Alectinib treatment should be stopped permanently. Method of administration Alectinib is for oral use. The hard capsules must be swallowed whole, and they must not be opened or dissolved. They have to be taken with food.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.